MétaCan
Menu
← Back to cohort
Record W4416688580 · doi:10.5489/cuaj.9329

Contemporary outcomes and disease burden of high-grade T1 bladder cancer

2025· article· en· W4416688580 on OpenAlexvenueno aff
Agustín Pérez-Londoño, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Heidi J. Rayala, Peter Chang, Andrew Wagner, Joaquim Bellmunt, Aria F. Olumi, Boris Gershman

Bibliographic record

VenueCanadian Urological Association Journal · 2025
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsBladder cancerDisease burdenDiseaseBurden of diseaseCancer

Abstract

fetched live from OpenAlex

INTRODUCTION: High-grade T1 (HGT1) bladder cancer is considered to have high five-year recurrence and progression rates, at 50-70% and 25-50%, respectively; however, contemporary data are lacking. We examined the contemporary outcomes of HGT1 bladder cancer to inform patient counseling, management, and clinical trial design. METHODS: We identified patients aged ≥18 years with a new diagnosis of HGT1 bladder cancer between 2010 and 2022 treated at our institution. Recurrence-free (RFS), progression-free (PFS), and cancer-specific (CSS) survival were estimated using the Kaplan-Meier method. Associations of baseline characteristics with outcomes were evaluated using Cox regression. RESULTS: A total of 213 patients were included, representing 332 cancer occurrences. Median age at diagnosis was 72 (interquartile range [IQR] 65-80) years. Median followup for RFS, PFS, and CSS was 13, 20, and 36 months, respectively. The one-, three-, and five-year event-free rates were 65%, 51%, and 48% for RFS; 85%, 78%, and 72% for PFS; and 99%, 95%, and 95% for CSS. There was a median of 1 (IQR 1-2) recurrence per patient, with a median time to first recurrence of seven months (IQR 4-14) and a median time between recurrences of seven months (IQR 5-18). Larger tumor size was associated with increased risks of recurrence. Receipt of adjuvant intravesical therapy was associated with reduced risks of recurrence and progression. CONCLUSIONS: Contemporary five-year recurrence and progression rates for HGT1 bladder cancer remain high at 53% and 28%, respectively. The disease burden is substantial, with a median time between recurrences of seven months. These results can inform patient counseling, management, and clinical trial design.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.275
Teacher spread0.257 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Urological Association Journal→Same topicBladder and Urothelial Cancer Treatments→French-language works237,207→